Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia

NCT03109093 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

83

Enrollment

OTHER

Sponsor class

Conditions

ALL, Recurrent, Adult

Interventions

DRUG: Blinatumomab

Sponsor

Goethe University